The loss of the identity of insulin-secreting beta cells in the islet of Langerhans, a process also called beta cell dedifferentiation, has been proposed to be a main reason for the development of ...

The combination of two drugs — an investigational drug used in conjunction with an already FDA-approved medication — improved lung function in patients with one form of cystic fibrosis, according to ...

A phase three clinical trial that UT Southwestern participated in determined that a three-drug combination improved lung function and reduced symptoms in cystic fibrosis (CF) patients who have a ...

-Combination of lumacaftor and ivacaftor is the first regimen designed to treat the underlying cause of CF in people with two copies of the F508del mutation, the most common form of the disease- -All ...

CAMBRIDGE, Mass., Jun 28, 2012 --- Adverse events were similar between treatment and placebo groups; most events were mild to moderate - --- Pivotal program to evaluate VX-809 (600mg) in combination ...

COYA 303 is an investigational biologic combination of COYA 301, Coya’s low-dose interleukin 2 (LD IL-2) and a GLP-1 receptor agonist (GLP-1RA), designed to deliver a multi-targeted immunomodulatory ...

Percutaneous and laparoscopic-assisted cryoablation of small renal cell carcinomas. Background: Combination of certain immunotherapies with TKI’s has been used with success in the treatment of ...